Shao Zonghong

[Expert Profile] Shao Zonghong, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in hematology in China, working in the Department of Hematology, General Hospital of Tianjin Medical University. He has long been dedicated to the clinical diagnosis, treatment, and scientific research of difficult hematological diseases such as myelodysplastic syndrome and myelofibrosis, and is an important leading figure in hematology in China.

[Education & Career] Professor Shao Zonghong graduated from Tianjin Medical College, completed systematic clinical training at the General Hospital of Tianjin Medical University, and further studied at famous international hematology centers. He has long served as Director of the Department of Hematology at Tianjin Medical University General Hospital, holding important academic positions including Vice Chair of the Hematology Branch of the Chinese Medical Association. He has presided over grants from the National Natural Science Foundation of China and major provincial and ministerial projects, and has accumulated profound academic achievements in the field of myelodysplastic syndrome and related conditions.

[Areas of Expertise] Professor Shao specializes in the diagnosis and treatment of myelodysplastic syndrome (MDS), myelofibrosis, aplastic anemia, and various difficult hematological diseases. He has extensive experience in precise subtyping of MDS (WHO classification and IPSS-R prognostic stratification), standardized application of hypomethylating agents and immunomodulatory therapy, and JAK inhibitor targeted therapy for myelofibrosis. He excels at managing difficult hematological patients with "long-term abnormal blood counts and recurrent transfusion dependence," helping numerous patients stabilize their conditions, prolong survival, and improve quality of life.

[Academic Achievements & Industry Contributions] Professor Shao has led a series of clinical and translational studies on MDS and related conditions, systematically evaluating the subtyping characteristics, prognostic factors, and treatment strategies of Chinese patients, with findings published in authoritative domestic and international journals. He has participated in the development of Chinese MDS diagnosis and treatment guidelines and expert consensus statements, actively promoted the clinical application of standardized MDS diagnosis and treatment and prognostic stratification systems, and led multi-center collaborative research and drug clinical trials, significantly improving the diagnosis and treatment level of difficult hematological diseases such as myelodysplastic syndrome in China.

[Clinical Practice & Outstanding Contributions] For decades on the clinical front lines, Professor Shao has treated tens of thousands of patients with MDS and various difficult hematological diseases, with patient coverage extending across northern China and nationwide. Leading his team, he has established a multidisciplinary collaborative system for difficult hematological diseases, providing clear diagnoses and developing standardized treatment plans for countless patients with "abnormal blood counts over many years." He values medical education and talent training, having trained a large number of hematology professionals, and is deeply trusted by patients and respected by peers alike. He is an important expert in hematology not only in Tianjin but nationwide.

[Honors & Reputation] Professor Shao Zonghong has long held academic positions including leader of the Red Blood Cell Diseases Group of the Hematology Branch of the Chinese Medical Association. He has presided over national-level projects including key grants from the National Natural Science Foundation of China, and is an authoritative expert in the field of red blood cell disorders in China. He has profound expertise in the diagnosis and treatment of difficult hematological diseases such as myelodysplastic syndrome (MDS) and myelofibrosis. He has led the establishment of a standardized MDS diagnosis and treatment and risk stratification system, systematically conducted research on innovative therapies such as hypomethylating agents, promoted the improvement of MDS diagnosis and treatment standards in China, and participated in the development of multiple hematology diagnosis and treatment guidelines. For decades on the clinical front lines, he has helped numerous difficult hematology patients receive clear diagnoses and standardized treatment, and is deeply trusted by patients and respected by peers alike.